In recent years, the use of positron emission tomography (PET) agents targeting prostate-specific membrane antigen (PSMA) has greatly improved the accuracy of prostate cancer (PCa) metastasis detection compared with conventional imaging [1, 2]. This evidence concerns the gene FOLH1 and prostate carcinoma.